A randomised trial of Conventional care versus Radioablation (stereotactic body radiotherapy) for Extracranial oligometastases
CORE is a phase II/III, multicentre, non-blinded, randomised controlled trial in patients with breast, prostate or non-small cell lung cancer (NSCLC) primary cancer to evaluate if the addition of stereotactic body radiotherapy (SBRT) to standard therapy improves progression-free survival outcomes in patients with extra-cranial metastases that have spread from either their lung, breast and/or prostate cancer.
Primary Sponsor
Collaborating Groups
Trans Tasman Radiation Oncology Group (TROG)
Final Accrual
245
Closing Date of Accrual
February 2019
Trial Chairperson
A/Prof David Pryor, Princess Alexandra Hospital, QLD
A/Prof Farshad Foroudi, Austin Health - Olivia Newton John Cancer and Wellness Centre, VIC
Trial Contact
CORE@trog.com.au
Related Post
NINJA Radiation Therapy Trial participant tells his journey to treatment
The journey to becoming the 200th participant for the
The gift that kept on giving
The NewyWay Coffee Collaboration Newcastle marketing agency, The Marketing
